Happy to be wrong here, but (to me), the results of the EFS represents progress and an achievement that is new to the company. Its not a report at a conference, or a media release of a series of patient outcomes, but a formal trial, and a report that brings a new level of evidence.
While the results are reflective of what is already known (performance compared to competitors results, and also compared to historical control data - actual improvements for the patients them selves) plus some new achievements, it may not be what is needed to spark interest in new buyers (investors) and an improvement in SP.
On the other hand, these results will likely support the next phase of the ongoing investigations that will be needed for progression to the next (hopefully commercialisation) stage.
The current results them self may or may not see a rise in SP, but, the commercial success (and the anticipated rise in SP) will need the results of the current study, so these results are adding 'value' even if not reflected in the SP
Opinion not advice
Happy to be wrong here, but (to me), the results of the EFS...
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |